Edition:
United States

Genomic Health Inc (GHDX.OQ)

GHDX.OQ on NASDAQ Stock Exchange Global Select Market

29.93USD
11:25am EST
Change (% chg)

$0.33 (+1.11%)
Prev Close
$29.60
Open
$29.55
Day's High
$29.93
Day's Low
$29.54
Volume
7,728
Avg. Vol
47,698
52-wk High
$34.02
52-wk Low
$26.43

Summary

Name Age Since Current Position

Kimberly Popovits

58 2012 Chairman of the Board, President, Chief Executive Officer

Gordon Cole

61 2016 Chief Financial Officer, Chief Operating Officer

Steven Shak

66 2014 Chief Scientific Officer

Phillip Febbo

50 2013 Chief Medical Officer

Laura Kammeyer

54 2014 Chief Communications Officer

Frederic Pla

2015 Chief Business and Product Development Officer

James Vaughn

2014 Chief Commercial Officer

Julian Baker

50 2012 Lead Independent Director

Felix Baker

47 2012 Independent Director

Fred Cohen

60 2002 Independent Director

Henry Fuchs

59 2013 Independent Director

Ginger Graham

62 2008 Independent Director

Geoffrey Parker

52 2016 Independent Director

Biographies

Name Description

Kimberly Popovits

Ms. Kimberly J. Popovits serves as Chairman of the Board, President, Chief Executive Officer of Genomic Health, Inc. Ms. Popovits has served President and Chief Executive Officer since January 2009, and as Chairman of the Board since March 2012. Prior to that, Ms. Popovits served as President and Chief Operating Officer since February 2002 and as a director since March 2002. From November 1987 to February 2002, Ms. Popovits served in various roles at Genentech, Inc., a biotechnology company, most recently serving as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech, she served as Division Manager, Southeast Region, for American Critical Care, a division of American Hospital Supply, a supplier of health care products to hospitals. Ms. Popovits holds a B.A. in Business from Michigan State University.

Gordon Cole

Mr. Gordon Bradley Cole serves as Chief Financial Officer, Chief Operating Officer of Genomic Health, Inc. Mr. Cole has served as Chief Operating Officer since January 2009 and has also served as Chief Financial Officer since June 2014, and from July 2004 until January 2011. Prior to that, Mr. Cole served as Executive Vice President, Operations from January 2008 and as Executive Vice President and Chief Financial Officer from July 2004 until January 2009. Mr. Cole also served as Secretary from February 2005 until July 2012. From December 1997 to May 2004, he served in various roles at Guidant Corporation, a medical device company, most recently serving as Vice President, Finance and Business Development for the Endovascular Solutions Group from January 2001 until May 2004. From July 1994 to December 1997, Mr. Cole was Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a medical device company that was acquired by Guidant Corporation. From December 1988 to February 1994, he served as Vice President, Finance and Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company. Mr. Cole holds a B.S. in Business from Biola University and an M.B.A. from San Jose State University.

Steven Shak

Dr. Steven Shak, M.D., serves as Chief scientific officer of Genomic Health, Inc. From July 1996 to October 2000, Dr. Shak served in various roles in Medical Affairs at Genentech, most recently as Senior Director and Staff Clinical Scientist. From November 1989 to July 1996, Dr. Shak served as a Director of Discovery Research at Genentech, where he was responsible for Pulmonary Research, Immunology, and Pathology. Prior to joining Genentech, Dr. Shak was an Assistant Professor of Medicine and Pharmacology at the New York University School of Medicine. Dr. Shak holds a B.A. in Chemistry from Amherst College and an M.D. from the New York University School of Medicine, and completed his post-doctoral training at the University of California, San Francisco.

Phillip Febbo

Dr. Phillip Febbo, M.D., serves as Chief Medical Officer of the Company, since August 2013. From July 2010 to August 2013, Dr. Febbo served as Director of Applied Genomics at the University of California, San Francisco. While at UCSF, Dr. Febbo was the Co-Leader of the Prostate Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. From September 2004 to June 2010, Dr. Febbo served as Associate Professor of Medicine and Molecular Genetics and Microbiology at Duke University Medical Center’s Institute of Genome Sciences and Policy. Dr. Febbo holds a B.A. in Biology from Dartmouth College and an M.D. from the University of California, San Francisco, and completed his internal medicine residency at the Brigham and Women’s Hospital.

Laura Kammeyer

Ms. Laura Leber Kammeyer serves as Chief Communications Officer of the Company, since December 2014. Prior to that, Ms. Kammeyer served as our Senior Vice President, Communications since November 2002. From 1992 to 2001, Ms. Kammeyer served in various roles at Genentech, Inc., a biotechnology company, most recently as Vice President, Corporate Communications. Ms. Kammeyer holds a Bachelor of Journalism from the University of Missouri, Columbia.

Frederic Pla

Mr. Frederic Pla, Ph.D., serves as Chief Business and Product Development Officer of the Company.

James Vaughn

Julian Baker

Mr. Julian C. Baker serves as Lead Independent Director of Genomic Health, Inc., effective March 1, 2012. He is a Managing Partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker's firm manages long-term investment funds, focused on publicly traded life sciences companies, for major university endowments and foundations. Mr. Baker's career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. Mr. Baker is also a director of Incyte Corporation. Mr. Baker served as a director of Trimeris, Inc. from April 2004 until November 2011.

Felix Baker

Dr. Felix J. Baker, Ph.D., serves as Independent Director of Genomic Health, Inc. Dr. Baker's firm manages long-term investment funds, focused on publicly traded life sciences companies, for major university endowments and foundations. Dr. Baker's career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker is also a director of Seattle Genetics, Inc., where he serves as lead independent director, and serves as the Chairman of the Board of Synageva, Inc. Dr. Baker served as a director of Ardea Biosciences, Inc. from February 2010 until its acquisition in June 2012, and a director of Trimeris, Inc. from April 2004 until November 2011.

Fred Cohen

Dr. Fred E. Cohen, Ph.D. M.D., serves as Independent Director of Genomic Health, Inc. He is a partner at TPG, a private equity firm he joined in 2001, and serves as co-head of TPG's biotechnology group. Dr. Cohen was an Adjunct Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco. Dr. Cohen serves as a director of BioCryst Pharmaceuticals, Inc., CareDx, Inc., Five Prime Therupeutics, Inc., Quintiles Transnational Holdings Inc., Roka Bioscience, Inc., Tandem Diabetes Care, Inc., Veracyte, Inc. and a number of privately held companies.

Henry Fuchs

Dr. Henry J. Fuchs M.D. serves as Independent Director of Genomic Health, Inc., effective September 17, 2013. Dr. Fuchs was Executive Vice President and Chief Medical Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company from September 2005 to December 2008 and served in multiple roles of increasing responsibility at Ardea Biosciences, Inc., a biotechnology company, first as Vice President, Clinical Affairs, then as President and Chief Operating Officer, and finally as President and Chief Executive Officer, from October 1996 until June 2005. From 1987 to 1996, Dr. Fuchs held various positions at Genentech Inc., a biotechnology company. Dr. Fuchs serves as a director of Mirati Therapeutics, Inc. and served as a director of Ardea Biosciences, Inc. from November 2001 to June 2012.

Ginger Graham

Ms. Ginger L. Graham serves as Independent Director of Genomic Health, Inc. Ms. Graham served as Faculty at Harvard Business School from October 2009 to June 2012 and was Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company, from September 2003 to March 2007, and served as Amylin’s President from September 2003 to June 2006. From 1994 to 2003, Ms. Graham held various positions with Guidant Corporation, including Group Chairman, Office of the President, President of the Vascular Intervention Group, and Vice President. From 1979 to 1994, Ms. Graham held various positions with Eli Lilly and Company, including President and Chief Executive Officer of Advanced Cardiovascular Systems, Inc. Ms. Graham currently serves as a director of Clovis Oncology, Inc., Walgreen Co. and a number of privately held companies. Ms. Graham holds a B.S. in Agricultural Economics from the University of Arkansas and an M.B.A. from Harvard University.

Geoffrey Parker

Mr. Geoffrey M. Parker is Independent Director of the Company. Mr. Parker also served as the Chief Financial Officer of Anacor Pharmaceuticals, Inc. from September 2010 to May 2015 and as the Vice President, Managing Director and Partner at the global investment banking and securities firm Goldman, Sachs & Co., leading their west coast Healthcare Investment Banking practice from April 1997 to April 2009. Mr. Parker is a director of ChemCentryx, Inc., Perrigo Company plc and Sunesis Pharmaceuticals, Inc. Mr. Parker holds an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from the Stanford Graduate School of Business.

Basic Compensation

Name Fiscal Year Total

Kimberly Popovits

3,851,640

Gordon Cole

1,829,200

Steven Shak

1,538,790

Phillip Febbo

--

Laura Kammeyer

--

Frederic Pla

1,797,760

James Vaughn

1,640,560

Julian Baker

159,773

Felix Baker

174,773

Fred Cohen

168,273

Henry Fuchs

176,773

Ginger Graham

163,773

Geoffrey Parker

252,554
As Of  30 Dec 2016

Options Compensation